Generic Amyvid Availability

Amyvid is a brand name of florbetapir F 18, approved by the FDA in the following formulation(s):

AMYVID (florbetapir f-18 - solution;intravenous)

  • Manufacturer: AVID RADIOPHARMS INC
    Approval date: April 6, 2012
    Strength(s): 10ML (13.5-51mCi/ML) [RLD], 10-30ML (13.5-51mCi/ML) [RLD], 10-50ML (13.5-51mCi/ML) [RLD]

Has a generic version of Amyvid been approved?

No. There is currently no therapeutically equivalent version of Amyvid available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Amyvid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
    Patent 7,687,052
    Issued: March 30, 2010
    Inventor(s): Kung; Hank F. & Kung; Mei-Ping
    Assignee(s): The Trustees of the University of Pennsylvania
    This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
    Patent expiration dates:
    • April 30, 2027
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
    Patent 8,506,929
    Issued: August 13, 2013
    Assignee(s): The Trustees of the University of Pennsylvania
    This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
    Patent expiration dates:
    • April 30, 2027
      ✓ 
      Patent use: AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • April 6, 2017 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web1)